Compare Cytokinetics Inc (CYTK) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Cytokinetics Inc trades at $76.48 (market cap $10.63B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: Cytokinetics Inc is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| CYTK | YMAX | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $87.26 | $13.26 |
52-Week Low | $34.31 | $7.27 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
YMAX trades at $7.635, down 0.97% on the day, with a bullish technical signal but bearish moving averages. The ETF shows a pattern of weekly dividend distributions, though recent payouts have decreased from $0.15 to $0.06, indicating potential income pressure. Key technical levels show support at $7 and resistance at $8, with RSI suggesting mild overbought conditions.
The outlook for YMAX hinges on its ability to sustain distributions amid cost concerns. Risks include the fund-of-funds fee structure and market volatility. Analyst sentiment is mixed, with some highlighting income appeal but cautioning on expense drag. Upside depends on stable option income generation in varying market regimes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
